CCO Oncology Podcast

Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Episode Summary

Listen to Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and Helena A. Yu, MD, answer audience questions from a live CCO webinar regarding clinical data on antibody–drug conjugates in NSCLC, including biomarker testing, patient selection, and toxicity management.

Episode Notes

In this episode,Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and  Helena A. Yu, MD, answer audience questions from a live webinar regarding clinical data on antibody–drug conjugates in NSCLC including:

• Biopsies and biomarker testing considerations
• Tumor heterogeneity and targeting of brain metastases
• Liquid biopsies
• Sequencing of ADCs following previous therapy
• Toxicity management

Presenters:

Egbert F. Smit, MD, PhD
Professor
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands
Department of Thoracic Oncology
Netherlands Cancer Institute
Amsterdam, Netherlands

David Planchard, MD, PhD
Head of Thoracic Group
Department of Medical Oncology
Institute Gustave Roussy
Villejuif, France

Helena A. Yu, MD
Assistant Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Content based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc.

Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC - Oncology - Clinical Care Options (clinicaloptions.com)

Link to full program:
https://bit.ly/3fr2G6G